Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial

摘要

Abstract Patients with COVID-19 have shown melatonin deficiency. We evaluated the efficacy and safety of administration oral melatonin in patients with COVID-19-induced pneumonia. Patients were randomly assigned in a 1:1 ratio to receive melatonin plus standard treatment or standard treatment alone. The primary outcomes were mortality rate and requirement of IMV. The clinical status of patients was recorded at baseline and every day over hospitalization based on seven-category ordinal scale from 1 (discharged) to 7 (death). A total of 226 patients (109 in the melatonin group and 117 in the control group) were enrolled (median age; in melatonin group: 54.60?±?11.51, in control group: 54.69?±?13.40). The mortality rate was 67 in the melatonin group and 94 in the control group (OR; 7.75, 95 CI, 3.27–18.35, P?